Please login to the form below

Not currently logged in
Email:
Password:

orphan drugs

This page shows the latest orphan drugs news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca buys FDA priority review voucher from Sobi

AstraZeneca buys FDA priority review voucher from Sobi

The FDA’s PRV is used as an incentive for companies to invest in orphan drugs, by promising a cost reduction for the application fee for future products and a ... hundreds of millions for the most promising drugs.

Latest news

  • The most annoying ‘F’ word in healthcare The most annoying ‘F’ word in healthcare

    We know that some of the largest employers in the US participate in these plans and we also know that fail first policies are being applied to the coverage of drugs ... In other words, these policies are not reserved for the orphan disease drugs or the

  • Europe urged to adapt faster to gene therapy challenges Europe urged to adapt faster to gene therapy challenges

    Existing models include conditional reimbursement, such as England’s Cancer Drugs Fund and Scotland’s fund for ultra-orphan drugs. ... Pay-for-performance deals for traditional drugs are also becoming established in Europe and the US, linking price

  • Sobi takes ownership of rare disease drug Gamifant for $518m Sobi takes ownership of rare disease drug Gamifant for $518m

    This gives companies investing in orphan drugs a cost reduction for the application fee for future products and shortens the review period, and can be used or sold on to other

  • Stream on Stream on

    That’s it. The other drugs will have their own Netflix models. ... In other words, we’re not seeing any $1m-per- year therapies or ultra-orphan drugs being made available under these models.

  • Orphan drugs market to soar to $224bn by 2024 Orphan drugs market to soar to $224bn by 2024

    for orphan drugs through to 2024, according to a report by Evaluate Pharma. ... However this bonanza has generated scrutiny of industry prices, and the very favourable incentives for orphan drugs.

More from news
Approximately 81 fully matching, plus 90 partially matching documents found.

Latest Intelligence

  • Biopharma and orphan drugs Biopharma and orphan drugs

    Price concerns. Another argument in favour of the support given to the orphan drug industry is that rare disease drugs generate lower revenues than mass market medicines. ... According to a 2019 study, for example, the mean orphan drug cost per patient

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    The 11 drugs are almost universally accelerated in their development by orphan drug status or other designations intended to spur closer cooperation between regulators and drug developers with the intention of ... The 11 drugs identified collectively

  • Pharma funding and M&A in 2020 Pharma funding and M&A in 2020

    sectors of gene therapy, immune-oncology and orphan drugs therapeutic categories. ... By contrast, the larger pharmaceutical companies often have both the time and resources to see these drugs over the line.

  • The changing nature of approvals – what does the future hold? The changing nature of approvals – what does the future hold?

    However, rare diseases and orphan drugs are also emerging as important focal areas. ... The incentives (market exclusivity, reduced regulatory fees, subsidies) introduced for orphan drugs under the US Orphan Drug Act (ODA) and later with the Committee

  • Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019 Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

    This year's list contains no cancer drugs. Orphan drugs and breakthrough therapies dominate the list of seven drugs predicted to launch this year and forecast to achieve blockbuster status by ... The third theme is niche versus mass clinical impact. A

More from intelligence
Approximately 14 fully matching, plus 41 partially matching documents found.

Latest appointments

  • New hires at Crescendo, Healx and Galecto New hires at Crescendo, Healx and Galecto

    Prior to joining Healx, he worked as CMO at Aparito and as therapeutic area head of orphan drugs at Mereo BioPharma. ... Before that, he lead global R&D at Almirall, which involved 500 staff and the development and approval of several new drugs in a

  • New hires at FibroGen, Saniona and Turbine New hires at FibroGen, Saniona and Turbine

    He has extensive experience of the regulatory, access, commercial and financial environment for developing orphan drugs in the US – a region which is directly relevant to Saniona’s next phase of ... The first members of the SAB bring 70 years of

  • Orchard Therapeutics appoints Mark Rothera as CEO Orchard Therapeutics appoints Mark Rothera as CEO

    market, and launching several orphan drugs.

  • XenoGesis appoints business development consultant XenoGesis appoints business development consultant

    business.”. Currently, Mogle serves as chief executive officer of RareMoon Consulting, a non-clinical development and regulatory affairs consulting firm specialising in orphan drugs she co-founded earlier this year. ... She has previously held

  • Hansa Medical strengthens management team Hansa Medical strengthens management team

    In his new role, van Troostwijk will be responsible for overseeing the firm's commercial assessments of its lead project IdeS, an orphan drug in development for organ rejection. ... IdeS.”. Van Troostwijk brings over 20 years of sales and marketing

More from appointments
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 5 fully matching, plus 17 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics